Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H20F2N2O4.CH4O3S.H2O |
Molecular Weight | 540.534 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CS(O)(=O)=O.C[C@H]1NCC2=CC(=CC=C12)C3=CC=C4C(=O)C(=CN(C5CC5)C4=C3OC(F)F)C(O)=O
InChI
InChIKey=IGTHEWGRXUAFKF-NVJADKKVSA-N
InChI=1S/C23H20F2N2O4.CH4O3S.H2O/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30;1-5(2,3)4;/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30);1H3,(H,2,3,4);1H2/t11-;;/m1../s1
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067888.pdfCurator's Comment: description was created based on several sources, including, http://www.shijiebiaopin.com/upload/product/201233119022430.pdf
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067888.pdf
Curator's Comment: description was created based on several sources, including, http://www.shijiebiaopin.com/upload/product/201233119022430.pdf
Garenoxacin is an antibacterial agent active against a range of aerobic Gram-positive and Gram-negative bacteria. It exerts its action by inhibiting bacterial DNA gyrase and topoisomerase IV. The drug was withdrawn from the market in Europe and was never approved in the USA. Garenoxacin is still marketed in Japan under the name Geninax.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363076 |
|||
Target ID: CHEMBL2311224 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | GARENOXACIN MESYLATE Approved UseAcute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Uncomplicated skin and skin structures infections, Complicated skin and skin structure infections including diabetic foot infections, Complicated intra-abdominal infections, including post-surgical and acute pelvic infections. |
|||
Curative | GARENOXACIN MESYLATE Approved UseLaryngopharyngitis, Tonsillitis (including peritonsillitis and peritonsillar abscess), Acute bronchitis, Pneumonia, Secondary infection in chronic respiratory lesion, Otitis media, Sinusitis |
|||
Curative | GARENOXACIN MESYLATE Approved UseAcute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Uncomplicated skin and skin structures infections, Complicated skin and skin structure infections including diabetic foot infections, Complicated intra-abdominal infections, including post-surgical and acute pelvic infections. |
|||
Curative | GARENOXACIN MESYLATE Approved UseAcute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Uncomplicated skin and skin structures infections, Complicated skin and skin structure infections including diabetic foot infections, Complicated intra-abdominal infections, including post-surgical and acute pelvic infections. |
|||
Curative | GARENOXACIN MESYLATE Approved UseAcute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Uncomplicated skin and skin structures infections, Complicated skin and skin structure infections including diabetic foot infections, Complicated intra-abdominal infections, including post-surgical and acute pelvic infections. |
|||
Curative | GENINAX Approved UseLaryngopharyngitis, Tonsillitis (including peritonsillitis and peritonsillar abscess), Acute bronchitis, Pneumonia, Secondary infection in chronic respiratory lesion, Otitis media, Sinusitis Launch Date2006 |
|||
Curative | GENINAX Approved UseLaryngopharyngitis, Tonsillitis (including peritonsillitis and peritonsillar abscess), Acute bronchitis, Pneumonia, Secondary infection in chronic respiratory lesion, Otitis media, Sinusitis Launch Date2006 |
|||
Curative | GENINAX Approved UseLaryngopharyngitis, Tonsillitis (including peritonsillitis and peritonsillar abscess), Acute bronchitis, Pneumonia, Secondary infection in chronic respiratory lesion, Otitis media, Sinusitis Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. | 1999 May |
|
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. | 2000 Dec |
|
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. | 2002 Mar |
|
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. | 2004 Apr |
|
Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice. | 2010 Apr |
Patents
Sample Use Guides
The MICs was 0.025-0.78 ug/ml against aerobic and facultative anaerobic Gram-positive bacteria, 0.00313-12.5 ug/ml against aerobic and facultative anaerobic Gram-negative bacteria, 0.1-3.13 ug/ml against obligate anaerobic Gram-positive bacteria and 0.05-0.78 ug/ml for obligate Gram-negative bacteria. The MICs against C. pneumoniae, C. psittaci, M. pneumoniae and Legionella spp., were 0.008, 0.002, 0.016, 0.0313 and 0.0039-0.0313 ug/ml, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5672
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
MM-77
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
DTXSID4048644
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
GENINAX
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | APPROVED JULY 2007 | ||
|
157690
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
223652-90-2
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
100000091589
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
SUB27012
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
OXI6EF55FR
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
C65801
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
DBSALT001994
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL215303
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY | |||
|
SUB25395
Created by
admin on Fri Dec 15 15:25:55 GMT 2023 , Edited by admin on Fri Dec 15 15:25:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD